$ARTV

Bush Jennifer sold $94K of ARTV

Bush Jennifer (COO, CLO, Compliance Officer) sold 8,391 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 on 2026-09-03.

Original reporting
SEC EDGAR · Bush Jennifer
Published Sep 4, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bearish
medium confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, providing new data for investors.

02

Market read

First‑report insider sale adds modest new information; limited trading relevance.

03

What to watch

The insider still holds a substantial position, indicating continued confidence.

Relevance 3/10Novelty 4/10Timing: same‑day filing

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ARTVBearishMedium confidence
Context

COO Jennifer Bush sold 8,391 shares for $93,606, reducing her stake to 329,529 shares.

Expected impact

modest short‑term price pressure

Evidence & confidence

The sale size is modest relative to market cap, but the insider remains a large holder, limiting downside risk.

Market effects

Biotech sector may see slight caution after insider sell.

US biotech equities could experience minor ripple.

Limited global impact.

Counterpoint

The sale could be routine liquidity for the executive, not a negative signal.

Key entities

  • Artiva Biotherapeutics, Inc.

    US‑listed biotech company (ticker ARTV).

  • Jennifer Bush

    Chief Operating Officer, Chief Legal Officer, and Compliance Officer of Artiva.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARTVMed

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a